Advanced Search

Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2001 June;40(2) > Minerva Pneumologica 2001 June;40(2):57-62



A Journal on Diseases of the Respiratory System

Official Journal of the Italian Society of Thoracic Endoscopy
Indexed/Abstracted in: EMBASE, Scopus

Frequency: Quarterly

ISSN 0026-4954

Online ISSN 1827-1723


Minerva Pneumologica 2001 June;40(2):57-62


Neltenexine in lung diseases: an open, randomised, controlled study versus N-acetylcysteine comparison

Caporalini R., Giosuè G. L.

Background. The aim of this study was to evaluate the efficacy and tolerability of a neltenexine therapy.
Methods. This open, controlled study vs N-acetylcysteine was carried out in 40 patients of both sexes affected by acute and chronic lung diseases that could benefit from mucolytic treatment (chronic bronchitis, bronchitis, pneumonia and tracheobronchitis). The exclusion criteria were allergy to tested drugs, evidence of asthma, cystic fibrosis, bronchiectasis, tuberculosis or lung cancer. The patients were randomly allocated to one of the following two possible treatments: neltenexine, 1 tablet twice daily for 11 days (neltenexine group, twenty patients); N-acetylcysteine, 2 sachets 100 mg, thrice a day, for 11 days (N-acetylcysteine group, twenty patients). The efficacy criteria were: difficulty in expectorating, cough, dyspnea, pulmonary auscultation.
Results. Statistically significant differences were found between the neltenexine and the N- acetylcysteine groups in terms of the decreases in the difficulty in expectorating (p<0.01), cough (p<0.05), pulmonary auscultation (p<0.05), from the baseline values to the values found at the time of the final examination. Tolerability was satisfactory in both groups.
Conclusions. These results confirmed the efficacy and tolerability of neltenexine in patients by acute and chronic lung diseases.

language: English


top of page